Company Overview and News

 
TCS set to be first Indian co with $100-bn market cap

2018-04-21 freepressjournal.in
Mumbai : Information technology bellwether Tata Consultancy Services (TCS) is closed to hitting the $100-billion mark in terms of market capitalisation as its share price surged nearly 7 per cent on Friday, adding about $6.2 billion to its valuation.
Upvote Downvote

 
Weak rupee, TCS mood-upper lift Nifty IT index to new high

2018-04-20 thehindubusinessline
Our Bureau The Nifty IT index on Friday registered a lifetime high on weak rupee against the US dollar and a robust growth guidance by Tata Consultancy Services.
Upvote Downvote

 
TCS m-cap nears $100 bn; investors richer by Rs 41,301 cr

2018-04-20 moneycontrol
TCS moved closer to the USD 100 billion mark in market capitalisation as its share price surged nearly 7 percent today, adding about USD 6.2 billion to its valuation.
Upvote Downvote

 
TCS at record closing high, just 1.5% shy of hitting $100bn market cap

2018-04-20 moneycontrol
Tata Consultancy Services share has rallied 6.62 percent to end at record closing high of Rs 3,402.45 on Friday after reporting healthy performance for the March quarter as well as FY18.
Upvote Downvote

 
TCS hits new record high, eyes $100 bn market capitalisation post Q4 FY18 result

2018-04-20 moneycontrol
Tata Consultancy Services share has rallied 6.5 percent intraday to hit a fresh record high of Rs 3,399.90 on Friday after reporting healthy performance for the March quarter as well as FY18. At 11:39 hours IST, the share price was quoting at Rs 3,383.00, up Rs 191.85, or 6.01 percent.
Upvote Downvote

 
Nifty IT index jumps 5% after rupee hits 13-month low, TCS adds Rs 40K cr to market cap post Q4 results

2018-04-20 moneycontrol
Not only TCS but also all other technology stocks rallied sharply on Friday, after the Tata Group firm reported highest ever dollar revenue growth in last 14 quarters in Q4 and the rupee hit 13-month low of 66.08 against the US dollar.
Upvote Downvote

 
Market Update: IT stocks rally with TCS gaining over 6%; Welspun India zooms 9%; Yes Bank top loser

2018-04-20 moneycontrol
The Indian equity market was trading on a flat to negative note on Friday afternoon with the Nifty shedding 13 points was trading at 10,551 while the Sensex was down 27 points or 0.08 percent.
Upvote Downvote

 
Market Live: Sensex weak as banks, global cues weigh; tech stocks extend rally

2018-04-20 moneycontrol
2:35 pm TCS eyes USD 100 billion in market cap: TCS is the most valued company at Dalal Street, with a market capitalisation of Rs 6.5 lakh crore and inching towards to become the first USD 100 billion company after its healthy earnings performance and strong commentary.
Upvote Downvote

 
Market Live: Nifty Bank falls 200 pts, IT index up 4%; TCS jumps 6%, RIL HDFC drag

2018-04-20 moneycontrol
12:45 pm Market Update: The market remained under selling pressure following negative lead from global stocks. But the sharp rally in technology stocks post TCS' Q4 FY18 result and a weak rupee continued to support benchmark indices.
Upvote Downvote

 
Market Update: IT stocks rally led by TCS; PSU banks drag as PNB, BOI fall 2-5%; Indigo hits new 52-week high

2018-04-20 moneycontrol
The Indian equity market was trading on a negative note on Friday afternoon with the Nifty shedding 21 points was trading at 10,543 while the Sensex was down 58 points or 0.17 percent.
Upvote Downvote

 
Market Live: IT only gainer among sectoral indices, TCS adds Rs 40,000 cr to market cap

2018-04-20 moneycontrol
11:50 am Market Update: The market remained under selling pressure due to global weakness, but the sharp rally in technology stocks post TCS Q4 results and weak rupee capped the losses of benchmark indices.
Upvote Downvote

 
TCS hits new record high post Q4 FY18 result; CLSA raises target to Rs 3,700/share

2018-04-20 moneycontrol
Tata Consultancy Services share has rallied 6.5 percent intraday to hit a fresh record high of Rs 3,399.90 on Friday after reporting healthy performance for the March quarter as well as FY18. At 11:39 hours IST, the share price was quoting at Rs 3,383.00, up Rs 191.85, or 6.01 percent.
Upvote Downvote

 
Market Live: 13-month low rupee lifts Nifty IT over 3%, but other sectoral indices down

2018-04-20 moneycontrol
10:55 am Buzzing: Eveready Industries plunged 10 percent after fair trade regulator CCI imposed a total fine of Rs 215 crore on Eveready as well as Indo National, industry grouping AIDCM and their officials for cartelisation in pricing of zinc carbon dry cell batteries.
Upvote Downvote

 
TCS hits new high after healthy Q4FY18 nos, up 44% in last 1 year; CLSA raises target to Rs 3,700

2018-04-20 moneycontrol
Tata Consultancy Services share price rallied more than 5 percent to hit a fresh record high of Rs 3,359.25 on Friday after reporting healthy performance for the March quarter as well as financial year 2017-18.
Upvote Downvote

 
Market Live: Sensex weak, rupee breaches 66/$; TCS hits record high, oil retailers rebound

2018-04-20 moneycontrol
9:55 am Rupee Trade: Rupee weakened by 25 paise to breach the 66-level and hit its 13-month low of 66.05 against the US dollar due to appreciation of the US currency overseas.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...